Immunomedics News (NASDAQ:IMMU)
| Latest Immunomedics News Headlines | | Date | Time | Source | | | 07/15/2008 | 9:20AM | PRNUS | BeaconEquity.com Issues TraderNotes on Active Stocks: CELI, UVSE, GSPG, GNTA, AAPL, IMMU, EXAS, EEE
DALLAS, July 15 /PRNewswire/ -- BeaconEquity.com announces the availability of a Technical Trade Alert for financial stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's TraderNotes include: CelebDirect Inc. (Pink Sheets: CELI), Universal... More...>> |
| 12/18/2007 | 3:49PM | PRNUS | Pacira Pharmaceuticals Names David M. Stack CEO and President
SAN DIEGO, Dec. 18 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., a leader in sustained release injectable technologies, today announced that David M. Stack has been selected as President, Chief Executive Office, and member of the Board of Directors.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)
Mr... More...>> |
| 06/13/2007 | 11:00AM | PRNUS | Immunomedics Set to Join Russell 3000 Index
MORRIS PLAINS, N.J., June 13 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that the Company is set to join the broad-market Russell 3000(R) Index when Russell Investment Group... More...>> |
| 06/11/2007 | 8:00AM | PRNUS | Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study
- Results Presented at the 12th Congress of European Hematology Association (EHA) -
VIENNA, Austria, June 11 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that data presented... More...>> |
| 06/05/2007 | 11:46AM | PRNUS | Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
- Results Presented at Society of Nuclear Medicine Annual Meeting -
WASHINGTON, June 5 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that initial results from a Phase I study... More...>> |
| 06/04/2007 | 3:00PM | PRNUS | Immunomedics Reports New and Updated Clinical Results from Dose De-Escalation Study with hA20 in Lymphoma Patients
-Results Presented at American Society of Clinical Oncology Annual Meeting-
CHICAGO, June 4 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Franck Morschhauser, MD, Centre... More...>> |
| 06/04/2007 | 9:00AM | PRNUS | Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
- Initial Phase II Study Results Presented at Society of Nuclear Medicine Annual Meeting -
WASHINGTON, June 4 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that its anti-carcinoembryonic... More...>> |
| 06/04/2007 | 8:00AM | PRNUS | Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
- Results from a Children's Oncology Group (COG) Study Presented at American Society of Clinical Oncology Annual Meeting -
CHICAGO, June 4 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today... More...>> |
| 05/30/2007 | 8:00AM | PRNUS | Immunomedics to Present at the Society of Nuclear Medicine 54th Annual Meeting
MORRIS PLAINS, N.J., May 30 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that four presentations will be given at the 54th Annual Meeting of the Society of Nuclear Medicine... More...>> |
| 05/29/2007 | 8:00AM | PRNUS | Immunomedics To Present at 43rd Annual Meeting of the American Society of Clinical Oncology
MORRIS PLAINS, N.J., May 29 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that three presentations will be given at the 43rd Annual Meeting of the American Society of Clinical... More...>> |
| 05/10/2007 | 8:00AM | PRNUS | Immunomedics to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
MORRIS PLAINS, N.J., May 10 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L. Sullivan, President and Chief Executive Officer, will be presenting at the Acumen... More...>> |
| 05/08/2007 | 4:30PM | PRNUS | Immunomedics Announces Third Quarter Fiscal 2007 Results
MORRIS PLAINS, N.J., May 8 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenues of $0.9 million and a net loss of $5.1 million, or $0.08 per share, for the third quarter... More...>> |
| 05/07/2007 | 4:30PM | PRNUS | Immunomedics Completes $24 Million Registered Direct Offering of Common Stock
MORRIS PLAINS, N.J., May 7 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU) today announced that it has completed its previously announced registered direct offering of 4,848,485 shares of its common stock to institutional investors at a price of $4.95 per share, for gross proceeds to the Company of approximately... More...>> |
| 05/02/2007 | 8:30AM | PRNUS | Immunomedics to Raise Gross Proceeds of $24 Million in Registered Direct Offering of Common Stock
MORRIS PLAINS, N.J., May 2 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU) today announced that it has entered into definitive agreements with institutional investors to sell 4,848,485 shares of its common stock in a registered direct offering resulting in gross proceeds to the Company of approximately $24... More...>> |
| 04/17/2007 | 4:00PM | PRNUS | Immunomedics Develops Novel Immunotoxin for Therapy of Prostate and Lung Cancers
LOS ANGELES, April 17 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today presented at the 2007 Annual Meeting of the American Association for Cancer Research results on the in vitro and... More...>> |
| 04/17/2007 | 2:40PM | PRNUS | Early Stage Pancreatic Cancer Expresses Antigen Targeted by Immunomedics' PAM4 Antibody
- Results Suggest PAM4 Can be Developed for Early Detection of Pancreatic Cancer -
LOS ANGELES, April 17 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, reported today in an oral presentation... More...>> |
| 02/08/2007 | 8:00PM | PRNUS | Immunomedics Announces Second Quarter Fiscal 2007 Results
MORRIS PLAINS, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenue of $3.4 million and a net loss of $4.5 million, or $0.08 per share, for the second quarter... More...>> |
| 01/10/2007 | 4:30PM | PRNUS | Immunomedics Mourns the Loss of Board Member Richard Pivirotto
MORRIS PLAINS, N.J., Jan. 10 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that Richard R. Pivirotto, the longest-serving independent director, since 1991, of the Company's... More...>> |
| 12/11/2006 | 8:00AM | PRNUS | Low Doses of Humanized Anti-Cd20 Antibody Reported Active in Non-Hodgkin's Lymphoma
- Follow-up Clinical Data Presented at the 48th Annual Meeting of American Society of Hematology -
ORLANDO, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, presented on Sunday... More...>> |
| 12/10/2006 | 9:00AM | PRNUS | Novel Protein Constructs Active Against Lymphoma In Animal Models
Fusion Proteins Targeting CD20 and CD22 Presented in Two Posters at American Society of Hematology (ASH) Annual Meeting
ORLANDO, Fla., Dec. 10 /PRNewswire-FirstCall/ -- Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies, today announced the development of new multivalent... More...>> |
|
|
|